CSIMarket



Moderna Inc.  (MRNA)
Other Ticker:  
 
 

MRNA's Revenue Growth by Quarter and Year

Moderna's Revenue results by quarter and year




MRNA Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 7,211.00 570.75 0.13
III Quarter September - 4,969.00 157.91 0.05
II Quarter June 4,749.00 4,354.00 66.35 0.07
I Quarter March 6,066.00 1,937.00 8.39 -
FY   10,815.00 18,471.00 803.40 0.25



MRNA Revenue second quarter 2022 Y/Y Growth Comment
Moderna Inc. reported Revenue growth of 9.07% year on year in the second quarter 2022, to $ 4,749.00 millions, this is lower than Moderna Inc.'s recent average Revenue surge of 461.41%.

Looking into second quarter 2022 results within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue growth. While Moderna Inc.' s Revenue increase of 9.07% ranks overall at the positon no. 1196 in the second quarter 2022.




MRNA Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 1163.43 % 438938.46 % -
III Quarter September - 3046.73 % 315720 % -37.5 %
II Quarter June 9.07 % 6462.17 % 94685.71 % -
I Quarter March 213.16 % 22987.01 % - -
FY   - 2199.1 % 321260 % -

Financial Statements
Moderna's second quarter 2022 Revenue $ 4,749.00 millions MRNA's Income Statement
Moderna's second quarter 2021 Revenue $ 4,354.00 millions Quarterly MRNA's Income Statement
New: More MRNA's historic Revenue Growth >>


MRNA Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 45.12 % 261.44 % 160 %
III Quarter September - 14.12 % 138 % -28.57 %
II Quarter June -21.71 % 124.78 % 690.82 % -
I Quarter March -15.88 % 239.38 % 6353.85 % -
FY (Year on Year)   - 2199.1 % 321260 % -




Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #124
Overall #1196

Revenue Y/Y Growth Statistics
High Average Low
3327.83 % 461.41 % -36.56 %
(Mar 31 2020)   (Sep 30 2019)
Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #124
Overall #1196
Revenue Y/Y Growth Statistics
High Average Low
3327.83 % 461.41 % -36.56 %
(Mar 31 2020)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Moderna's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
6249.58 % 443.15 % -100 %
(Mar 31 2020)  


MRNA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2022 Moderna Inc. realized fall in Revenue sequentially by -21.71% to $ 4,749.00 millions, from $ 6,066.00 millions declared in the previous reporting period.

Although seasonal circumstance usually energize II. Quarter 2022 performance, this simply could not be enough to recover MRNA's II. Quarter 2022 outcome, Chloe  D. Jackson, Biotechnology & Pharmaceuticals industry insider said.

Within Biotechnology & Pharmaceuticals industry 39 other companies have achieved higher Revenue quarter on quarter growth. While Moderna's Revenue growth quarter on quarter, overall rank is 1936.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #40
Healthcare Sector #240
Overall #1936
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #40
Healthcare Sector #240
Overall #1936
Revenue Q/Q Growth Statistics
High Average Low
6249.58 % 443.15 % -100 %
(Mar 31 2020)  


MRNA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2022 Moderna Inc. disclosed fall in Revenue from the previous quarter by -21.71% to $ 4,749.00 millions, from $ 6,066.00 millions released in the previous quarter.

Some seasonal circumstance could not salvage the II. Quarter for the Moderna Inc., Chloe  D. Jackson, Biotechnology & Pharmaceuticals industry insider wrote, she voiced little pessimism conserning MRNA's outlook and wrote that average quarter on quarter Revenue growth is at 443.15% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 39 other companies have achieved higher Revenue quarter on quarter growth. While Moderna's Revenue growth quarter on quarter, overall rank is 1936.


Moderna's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 22,995.00 $ 22,600.00 $ 18,471.00 $ 11,830.75 $ 7,019.66
Y / Y Revenue Growth (TTM) 227.58 % 727.23 % 2199.12 % 4982.33 % 9269.14 %
Year on Year Revenue Growth Overall Ranking # 50 # 7 # 10 # 6 # 4
Seqeuential Revenue Change (TTM) 1.75 % 22.35 % 56.13 % 68.54 % 156.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 2114 # 42 # 59 # 12 # 17




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2022 period, Moderna's cumulative twelve months Revenue were $ 22,995 millions, company would post below average annual Revenue growth of 156.94% year on year, if the fiscal year would end at Jun 30 2022.
A slow-down in the Moderna's Revenue growth from the 6066% growth in Mar 31 2022.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 50.

Revenue TTM Q/Q Growth Statistics
High Average Low
3327.83 %
461.41 %
-36.56 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 63
Healthcare Sector # 12
Overall # 50

Revenue TTM Y/Y Growth Statistics
High Average Low
532643.15 %
112106.14 %
227.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 310
S&P 500 # 2114
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2022 period, Moderna's cumulative twelve months Revenue were $ 22,995 millions, company would post below average annual Revenue growth of 227.58% year on year, if the fiscal year would end at Jun 30 2022.
A slow-down in the Moderna's Revenue growth from the 6066% growth in Mar 31 2022.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 50.

Revenue TTM Q/Q Growth Statistics
High Average Low
3327.83 %
461.41 %
-36.56 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 63
Healthcare Sector # 12
Overall # 50

Revenue TTM Y/Y Growth Statistics
High Average Low
532643.15 %
112106.14 %
227.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 310
S&P 500 # 2114




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRNA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for MRNA's Competitors
Revenue Growth for Moderna's Suppliers
Revenue Growth for MRNA's Customers

You may also want to know
MRNA's Annual Growth Rates MRNA's Profitability Ratios MRNA's Asset Turnover Ratio MRNA's Dividend Growth
MRNA's Roe MRNA's Valuation Ratios MRNA's Financial Strength Ratios MRNA's Dividend Payout Ratio
MRNA's Roa MRNA's Inventory Turnover Ratio MRNA's Growth Rates MRNA's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2022
Pacific Biosciences Of California Inc.15.87%$ 15.867 millions
Signify Health Inc.15.70%$ 15.695 millions
Si bone inc.15.28%$ 15.279 millions
Aspira Women s Health Inc.14.84%$ 14.842 millions
Ensign Group Inc14.71%$ 14.713 millions
Northwest Biotherapeutics inc14.66%$ 14.663 millions
Atrion Corporation14.50%$ 14.497 millions
Pulmonx Corporation14.32%$ 14.316 millions
Oncocyte Corporation14.12%$ 14.121 millions
Option Care Health Inc.14.01%$ 14.013 millions
Insulet Corporation13.75%$ 13.754 millions
Cumberland Pharmaceuticals Inc.13.73%$ 13.734 millions
Rigel Pharmaceuticals Inc13.53%$ 13.527 millions
Acadia Healthcare Company Inc.13.46%$ 13.465 millions
Adaptive Biotechnologies Corporation13.39%$ 13.388 millions
Surgery Partners Inc.13.27%$ 13.271 millions
Penumbra Inc13.07%$ 13.072 millions
Corcept Therapeutics Inc12.88%$ 12.882 millions
Pieris Pharmaceuticals Inc.12.57%$ 12.572 millions
Chimerix inc.12.53%$ 12.532 millions
Radius Health inc.12.53%$ 12.526 millions
American Shared Hospital Services12.47%$ 12.466 millions
Optinose Inc.12.12%$ 12.121 millions
Halozyme Therapeutics Inc.11.66%$ 11.660 millions
Cytomx Therapeutics Inc.11.52%$ 11.524 millions
Nabriva Therapeutics Plc11.50%$ 11.501 millions
Puma Biotechnology Inc.11.49%$ 11.490 millions
Maravai Lifesciences Holdings Inc.11.46%$ 11.460 millions
Bio techne Corp11.27%$ 11.273 millions
Hanger inc.11.12%$ 11.115 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DUETU's Profile

Stock Price

DUETU's Financials

Business Description

Fundamentals

Charts & Quotes

DUETU's News

Suppliers

DUETU's Competitors

Customers & Markets

Economic Indicators

DUETU's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071